Zusammenfassung
Hintergrund
Ein monozentrisches Kollektiv von 114 Patienten mit hämatogen metastasierten HNO-Tumoren wurde mit der Fragestellung untersucht, welche Parameter das Überleben beeinflussten.
Patienten und Methoden
Primärer Endpunkt der retrospektiven Untersuchung war das Überleben mit Fernmetastasen, sekundärer das Gesamtüberleben. Als potenziell endpunktrelevante Einflussparameter wurden Primärtherapie, Lokalrezidiv, Zweittumor, palliative Chemotherapie (CHT) und Radiotherapie (RT) sowie der Karnofsky-Performance-Status (KPS) zum Zeitpunkt der Metastasendiagnose univariat (Log-rank-Test) bzw. multivariat (Cox-Regression) analysiert.
Ergebnisse
Palliative CHT (p=0,0020) und der KPS bei Erstdiagnose von Metastasen (p=0,0011) beeinflussten univariat signifikant positiv die mediane Überlebenswahrscheinlichkeit mit Metastasen (8,2 Monate), als unabhängiger prognostischer Parameter verblieb der KPS (p=0,0013). Primärtherapie (p=0,0139), lokale Tumorkontrolle (p=0,0106) und der KPS (p=0,0096) beeinflussten univariat signifikant positiv die mediane Gesamtüberlebenswahrscheinlichkeit (18,5 Monate), ebenso multivariat (p=0,0123 bzw. p=0,0063 bzw. p=0,0197).
Schlussfolgerung
Als prognostisch unabhängiger Parameter für das Überleben mit Metastasen und das Gesamtüberleben verblieb der KPS zum Zeitpunkt der Metastasendiagnose. Solange eine Lebensverlängerung nicht evident ist, sollten daher in der palliativen Therapie die Stabilisierung des KPS und der Lebensqualität im Vordergrund stehen.
Abstract
Questions
The objective of this retrospective analysis was to investigate parameters with a potential impact on survival in a collective of 114 patients with distant metastatic disease after head and neck cancer.
Patients and methods
The primary endpoint was the survival with distant metastatic disease, the secondary endpoint was overall survival. Primary therapy, local recurrence, second neoplasms, palliative chemotherapy (CHT) and radiotherapy (RT), as well as Karnofsky performance status (KPS) at the time of diagnosis of the metastases were analyzed as potential impact parameters using the log-rank test with subsequent Cox regression analysis.
Results
Palliative CHT (P=0.0020) and KPS (P=0.0011) had a significant positive impact on the median survival probability with metastases (8.2 months) using the log-rank test, KPS at the time of diagnosis of metastases remained as an independent prognostic parameter in the Cox regression (P=0.0013). Primary therapy, local tumor control and KPS had a significant positive influence on the median overall survival probability (18.5 months) univariately (P=0.0139, P=0.0106, P= 0.0096) and multivariately (P=0.0123, and P=0.0063, P=0.0197, respectively).
Conclusions
KPS at the time of diagnosis of metastases is an independent prognostic parameter for both endpoints. Lacking evidence for life prolongation, palliative therapies should therefore first and foremost focus on the stabilization of the KPS.
Literatur
Adamo V, Ferraro G, Pergolizzi S et al. (2004) Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol 40: 525–531
Airoldi M, Cattel L, Marchionatti S et al. (2003) Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Am J Clin Oncol 26: 378–381
Arcangeli G, Giovinazzo G, Saracino B et al. (1998) Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys 42: 1119–1126
Ayache S, Peng J, Chatelain D et al. (2005) Therapeutic management of laryngeal cancer. Results of a study of 356 patients from the Cancer Registry of the Somme, France. Acta Otolaryngol 125: 1323–1326
Baumann I, Seibolt M, Zalaman I et al. (2006) Quality of life in patients with oropharyngeal carcinoma after primary surgery and postoperative irradiation. J Otolaryngol 35: 332–337
Baumann I, Seibolt M, Zalaman IM et al. (2006) Quality of life in patients with oropharyngeal carcinoma: Gender influences the subjective evaluation. HNO 54: 376–381
Bilde A, Von BC, Mortensen J et al. (2006) The role of SPECT-CT in the lymphoscintigraphic identification of sentinel nodes in patients with oral cancer. Acta Otolaryngol 126: 1096–1103
Buckley JG, Ferlito A, Shaha AR, Rinaldo A (2001) The treatment of distant metastases in head and neck cancer--present and future. ORL J Otorhinolaryngol Relat Spec 63: 259–264
Budach W, Hehr T, Budach V et al. (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6: 28
Calhoun KH, Fulmer P, Weiss R, Hokanson JA (1994) Distant metastases from head and neck squamous cell carcinomas. Laryngoscope 104: 1199–1205
Catimel G, Vermorken JB, Clavel M et al. (1994) A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5: 543–547
de Mulder PH (1999) The chemotherapy of head and neck cancer. Acta Otorhinolaryngol Belg 53: 247–252
Fanucchi M, Khuri FR (2004) Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 31: 809–815
Ferlito A, Shaha AR, Silver CE et al. (2001) Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec 63: 202–207
Forastiere AA, Metch B, Schuller DE et al. (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10: 1245–1251
Gebbia V, Testa A, Di GC et al. (1995) Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. Am J Clin Oncol 18: 293–296
Genet D, Cupissol D, Calais G et al. (2004) Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol 27: 472–476
Hao D, Ritter MA, Oliver T, Browman GP (2006) Platinum-based concurrent chemoradiotherapy for tumors of the head and neck and the esophagus. Semin Radiat Oncol 16: 10–19
Haughey BH, Gates GA, Arfken CL, Harvey J (1992) Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann Otol Rhinol Laryngol 101: 105–112
Hennemann B (2006) Palliative chemotherapy of head and neck cancer: present status and future development. Laryngorhinootologie 85: 172–178
Herborn CU, Unkel C, Vogt FM et al. (2005) Whole-body MRI for staging patients with head and neck squamous cell carcinoma. Acta Otolaryngol 125: 1224–1229
Hoegler D (1997) Radiotherapy for palliation of symptoms in incurable cancer. Curr Probl Cancer 21: 129–183
Jackel MC, Reck R (2006) Transoral resection of locally advanced squamous cell carcinoma of the lateral oropharynx: combination of CO2 laser microsurgery with flap reconstruction. HNO 54: 605–610
Jacobs C, Lyman G, Velez-Garcia E et al. (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257–263
Kirkbride P, Mackillop WJ, Priestman TJ et al. (1996) The role of palliative radiotherapy for bone metastases. Can J Oncol 6 [Suppl 1]: 33–38
Konski A, Feigenberg S, Chow E (2005) Palliative radiation therapy. Semin Oncol 32: 156–164
Ledeboer QC, Van d V, De Boer MF et al. (2006) Palliative care for head and neck cancer patients in general practice. Acta Otolaryngol 126: 975–980
Leon X, Quer M, Diez S et al. (1999) Second neoplasm in patients with head and neck cancer. Head Neck 21: 204–210
Moosmann P, Egli F, Stahel RA, Jost L (2003) Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie 26: 568–572
Piccirillo JF (2000) Importance of comorbidity in head and neck cancer. Laryngoscope 110: 593–602
Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949–955
Pinto HA, Jacobs C (1991) Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am 5: 667–686
Ricke J, Wust P, Wieners G et al. (2005) CT-guided interstitial single-fraction brachytherapy of lung tumors: phase I results of a novel technique. Chest 127: 2237–2242
Saxman S, Mann B, Canfield V et al. (1998) A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 21: 398–400
Schrijvers D, Vermorken JB (2000) Role of taxoids in head and neck cancer. Oncologist 5: 199–208
Schwentner I, Obrist P, Thumfart W, Sprinzl G (2006) Distant metastasis of parotid gland tumors. Acta Otolaryngol 126: 340–345
Shah JP, Lydiatt W (1995) Treatment of cancer of the head and neck. CA Cancer J Clin 45: 352–368
Shaw HJ (1985) Palliation in head and neck cancer. J Laryngol Otol 99: 1131–1142
Simon C, Plinkert PK (2006) Transoral resection of locally advanced squamous cell carcinoma of the side wall of the oropharynx: multimodal treatment concepts in transition. HNO 54: 589–590
Uppelschoten JM, Wanders SL, de Jong JM (1995) Single-dose radiotherapy (6 Gy): palliation in painful bone metastases. Radiother Oncol 36: 198–202
Werner JA (2005) Sentinel lymphadenectomy as a staging procedure. HNO 53: 511–512
Wulf J, Haedinger U, Oppitz U et al. (2004) Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 60: 186–196
Interessenkonflikt
Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dietl, B., Marienhagen, J., Schaefer, C. et al. Überleben mit hämatogen metastasierten HNO-Tumoren. HNO 55, 785–791 (2007). https://doi.org/10.1007/s00106-006-1522-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00106-006-1522-4